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CASE REPORT

Is Rocky Mountain Spotted Fever Transmitted in Maine?
Eric Ray MD
Maine Medical Center, Department of Internal Medicine/Graduate Medical Education, Portland, ME

Introduction:

Tick-borne disease occurs worldwide, and, recently, its distribution has been changing. Rocky Mountain
spotted fever (RMSF) is widespread across the United States and is being monitored for introduction to
non-endemic areas.

Clinical findings: A 65-year-old male presented to the emergency department with fevers, myalgias, arthralgias, and
a maculopapular rash of unclear etiology. He had a history of psoriatic arthritis under treatment with
adalimumab, as well as exposure to local ticks, but no known recent bites. Initial testing showed
transaminitis, worsened chronic thrombocytopenia, and slight neutropenia with an absolute neutrophil
count of 2330 cells/µL (reference value: 2400-7600 cells/µL). His tick panel was negative for Lyme,
anaplasma, babesia, and ehrlichia. The patient was stable and discharged.
Diagnoses,
Interventions,
and Outcomes:

The patient was evaluated in the clinic and found to have improving symptoms but worsening transaminitis.
He was empirically given doxycycline, and his repeat tick panel was also negative for Lyme, anaplasma,
babesia, and ehrlichia. Abdominal ultrasound was unremarkable, and viral serologies were negative for
hepatitis B and C, HIV, cytomegalovirus, and Epstein-Barr virus. His subsequent testing was positive
for Spotted Fever Group IgG. He completed empiric treatment, and his symptoms and lab abnormalities
resolved. The case was reported to the state of Maine Center of Disease Control and Prevention.

Conclusions:

This case does not meet requirements for diagnostic confirmation of RMSF, but it illustrates the
diagnostic considerations for tick-borne febrile illness in Maine.
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CASE PRESENTATION
A 65-year-old male presented to the emergency
department in late August. He reported 10 days
of fevers, myalgias, fatigue, night sweats, and
arthralgias. He also noticed a rash on his torso,
back, and extremities over the previous five
days. He was being treated with adalimumab
for psoriatic arthritis and had contracted Lyme
disease and ehrlichiosis 12 years earlier. He had
a mild transaminitis and worsening of chronic
thrombocytopenia (approximately 100 000 to 72
000/µL). Lyme antibodies were undetectable.
Polymerase chain reaction (PCR) tests were
negative for anaplasmosis, babesiosis, and
ehrlichiosis. The patient was clinically stable for
discharge.
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In a clinic visit 5 days later, the patient’s fevers
and rash had improved. He admitted frequent tick
exposure in wooded areas but denied recent bites
or travel. He had a faint maculopapular rash with
satellite lesions of the upper extremities. Repeat
labs showed worsening alanine transaminase 83 to
261 (0-40 U/L) and aspartate transaminase 73 to
174 (0-37 U/L). He was given empiric doxycycline
pending further workup 16 days after the onset of
his symptoms.
Abdominal ultrasound, creatinine kinase, and viral
serologies were unremarkable. His repeat tick
panels remained negative. At a follow-up clinic
visit after 9 days of doxycycline treatment, he only
had mild residual fatigue. The next day, testing for
the Spotted Fever Group Antibody IgG resulted as
1:256 (reference value <1:64) with negative IgM,
concerning for recent or current infection. Repeat
labs showed resolution of all prior abnormalities.
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DISCUSSION
While the American dog tick (Dermacentor
variabilis) exists in Maine, it is not known to carry
the Rickettsia rickettsii (R. rickettsii) bacterium that
causes Rocky Mountain spotted fever (RMSF).1
There are no confirmed cases of RMSF within the
state. RMSF is rarely seen and typically associated
with travel exposure.1 In New England, the
known endemic tick illnesses are Lyme, babesia,
anaplasma, Borrelia miyamotoi (B. miyamotoi), and
the increasingly recognized Powassan virus. These
illnesses are transmitted by the blacklegged deer
tick Ixodes scapularis.
RMSF is a reportable disease classified with the
Spotted Fever Rickettsioses (SFR), which includes
illnesses by R. parkeri, R. species 364D, and R.
akari.2,3,4 These illnesses share cross-reactive
antibodies, manifest with similar constitutional
symptoms, and usually have an associated rash
or eschar (most cases of R. parkeri).2 R. rickettsii
is transmitted by the American dog tick east of the
Rocky Mountains and on the Pacific Coast. It is the
only SFR-linked tick in New England (Figure 1).2,5
RMSF was first described in the Rocky Mountains,
but 60% of cases occur in North Carolina,
Oklahoma, Arkansas, Tennessee, and Missouri
(Figure 2).2,6 Some tick species continue to expand
their range due to climate change, resurgence of
the white-tailed deer population, reforestation, and
dispersal by birds. This expansion is evidenced by
the northward movement of the lone star tick that
transmits ehrlichiosis.7,8 Since 2000, the annual
incidence of SFR has increased from 495 to 6248.
However, in 2017, fewer than 10 cases were reported
in Maine compared with 1439 cases of Lyme, 663
of anaplasmosis, and 118 of babesiosis.2,7
R. rickettsii has an incubation period of 3-12
days before manifestation of early symptoms (<5
days), including fever, headache, malaise, and
gastrointestinal distress. A maculopapular rash,
which can involve palms and soles, starts 2-4 days
after the fever. In untreated patients, late symptoms
usually present after 5 days and include a petechial
rash from vasculitis, organ failure, paralysis, and
encephalopathy. These late, severe manifestations
designate RMSF as the deadliest tick-borne illness
worldwide. With the introduction of tetracyclines,
the mortality rates associated with RMSF have
declined significantly to 5-10%.2,3,9
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The standard cross-reactive serological test
for all SFR-group diseases is the indirect
immunofluorescence antibody (IFA) for IgG against
the R. rickettsii antigen.2 Antibodies are detectable
7-10 days after infection. However, to diagnose a
recent infection, acute and convalescent serologies
obtained 2-4 weeks apart must reveal a fourfold
increase, often to ≥1:256.2,10 Titers usually wane to
<1:256 within a few months and are undetectable at
one year. In some cases, they may be elevated for up
to 4 years.10 The CDC (Centers for Disease Control
and Prevention) deems cases as “confirmed” if
both acute and convalescent titers reveal the
fourfold increase that indicates seroconversion.11
For more specific diagnosis of each SFR-group
disease, there is upcoming expanded access to
pan-Rickettsia PCR assays.9,11
In this patient, lab testing excluded anaplasma,
babesia, Lyme, and ehrlichiosis. He did not have
neurological manifestations of Powassan virus. He
was not tested for the remaining Ixodes scapularis
disease B. miyamotoi; however, with a rash that
occurs in <10% of B. miyamotoi cases and the
absence of sepsis, this finding is unlikely.12,13 While
the single-elevated SFR IgG titer raises some
concern for RMSF, the mild clinical course in an
untreated patient, lack of typical rash progression
from wrists/ankles to trunk, and late-summer timing
of the illness broaden the differential diagnosis.2,14
Additionally, other less-severe SFR diseases with
cross-reactive antibodies are possible culprits,
as are a variety of viral syndromes that may be
represented by the transaminitis and reactive
lymphocytosis (11%; 690/µL absolute count) in this
patient.
While we do not propose a new endemic area of
RMSF, the lack of widespread access to specific
diagnostic testing obscures the distribution of each
rickettsial disease. There is increasing recognition
of the changing distributions in tick-borne disease
in the Northeastern United States, including the
northward movement of the lone star tick. Given
the similar presentations of these illnesses, a
careful approach to the differential diagnosis and
confirmation of the diagnosis is essential, and it
may help highlight changes in areas where the
disease occurs.15
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Figure 1: Dermacentor variabilis (American Dog Tick)5
Reproduced with permission from URI TickEncounter Resource Center

Figure 2: Cases of Rocky Mountain Spotted Fever Reported to the CDC in 20146
Published by MaineHealth Knowledge Connection, 2020
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